<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754689</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10231</org_study_id>
    <secondary_id>2008-002500-26</secondary_id>
    <nct_id>NCT00754689</nct_id>
  </id_info>
  <brief_title>Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Double Blind, Placebo Controlled Randomized Study of the Efficacy and Safety of Two Rimonabant/Metformin Combinations for Reducing A1C in the Treatment of Patients With Type 2 Diabetes Mellitus Who Are Not on Current Drug Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate superiority of rimonabant/metformin
      combinations in Glycosylated Hemoglobin 1c (A1C) reduction over the corresponding single
      agent metformin and over rimonabant alone in patients with type 2 diabetes mellitus at 9
      months.

      The secondary objective is to investigate the effects of rimonabant/metformin combinations
      for reducing fasted plasma glucose, body weight and triglycerides, and raising High Density
      Lipoprotein Cholesterol (HDL-C) in comparison with metformin at 9 months.

      Another objective is to evaluate the safety of rimonabant in combination with metformin over
      a period of up to 52 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration per patient is up to 65 weeks: 1 - 2 weeks screening, up to 52 weeks double
      blind treatment, and 75 days post last dose. This study will end for all patients when the
      last patient has been treated for at least 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company decision taken in light of demands by certain national health authorities
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in A1C</measure>
    <time_frame>at 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in triglycerides</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in HDL-C</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500mg twice daily (bid) + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000mg bid + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rimonabant 20mg once daily (od) + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <other_name>SR141716</other_name>
    <other_name>Acomplia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of type 2 diabetes mellitus diagnosed prior to the screening visit 1 (ADA
             criteria)

          -  Patients must not have used any oral or injectable glucose lowering medication at
             least 12 weeks prior to the screening visit to establish a stable, comparable baseline
             A1C assessment in all patients

          -  A1C ≥7.0 % and ≤10.0 %

          -  Fasted plasma glucose at screening visit ≤260 mg/dL (14.44 mmol/L)

        Exclusion Criteria:

          -  Treatment with any anti-diabetic oral agent, or injectable antidiabetic agent within
             12 weeks prior to screening visit

          -  In the 3 months prior to the screening visit, use of any anti-obesity agent or drugs
             for weight loss, or administration of systemic corticosteroids for more than 7 days

          -  Presence of any severe medical or psychological condition that, in the opinion of the
             investigator, would compromise the patient's safe participation including uncontrolled
             serious psychiatric illness such a major depression within the last 2 years, and
             history of other severe psychiatric disorders

          -  Presence or history of cancer within the past five years

          -  Pregnant or breast-feeding women, or women of childbearing potential not protected by
             effective method of birth control

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rimonabant/metformin combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

